Clinical Trials : ACTH-Secreting Pituitary Adenoma

Terminated

Nombre del estudio: Long-term Cardiovascular Risk in Cured Cushing's Patients
Condición: Cushing's Disease
Fecha: 2009-04-13

Not yet recruiting

Nombre del estudio: Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition
Condición: Iatrogenic Cushing's Disease
Fecha: 2017-03-17
Intervenciones:

Drug: AZD4017 and prednisolone

Completed

Nombre del estudio: Cognition, Steroids, and Imaging in Cushings Disease
Condición: Cushing Syndrome
Fecha: 2004-04-08

Completed

Nombre del estudio: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor
Condición:

Cushing's Disease
Corticotroph Adenoma Fecha: 2009-04-27
Intervenciones: Drug: Cabergoline Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of

Completed

Nombre del estudio: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease
Condición: Cushing's Syndrome
Fecha: 2004-07-30
Intervenciones: Drug: SOM230 s.c.

Completed

Nombre del estudio: Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools
Condición:

Pituitary Neoplasms
Prolactinoma
ACT
Fecha: 2013-01-22
Intervenciones: Other: Educational Intervention A brochure and access to a website including videos that contain detaile

Completed

Nombre del estudio: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease
Condición: Pituitary Neoplasm
Fecha: 2011-10-21
Intervenciones: Drug: Acthrel Ovine Corticorelin

Active, not recruiting

Nombre del estudio: Rhinological Outcomes in Endonasal Pituitary Surgery
Condición:

Pituitary Neoplasm
Pituitary Adenoma
Prolactinoma

Fecha: 2012-01-03

Completed

Nombre del estudio: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study.
Condición:

Cushing's Disease
Acromegaly
Fecha: 2013-02-15
Intervenciones: Drug: Pasireotide Pasireotide subcutaneous or Long Acting Release

Completed

Nombre del estudio: Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors
Condición:

Pituitary Tumor
ACTH-producing Pituitary Tumour

Fecha: 2016-04-20
Intervenciones: Drug: Pasireotide LAR Pasireotide LAR (SIGNIFOR® LAR)

Buscar resultados de ensayos clínicos

ACTH-Secreting Pituitary Adenoma - 32 Studies Found

Estado	Estudiar
Terminated	Nombre del estudio: Long-term Cardiovascular Risk in Cured Cushing's Patients Condición: Cushing's Disease Fecha: 2009-04-13
Not yet recruiting	Nombre del estudio: Targeting Iatrogenic Cushing's Syndrome With 11β-hydroxysteroid Dehydrogenase Type 1 Inhibition Condición: Iatrogenic Cushing's Disease Fecha: 2017-03-17 Intervenciones: Drug: AZD4017 and prednisolone
Completed	Nombre del estudio: Cognition, Steroids, and Imaging in Cushings Disease Condición: Cushing Syndrome Fecha: 2004-04-08
Completed	Nombre del estudio: Study of Cabergoline in Treatment of Corticotroph Pituitary Tumor Condición: Cushing's Disease Corticotroph Adenoma Fecha: 2009-04-27 Intervenciones: Drug: Cabergoline Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of
Completed	Nombre del estudio: A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease Condición: Cushing's Syndrome Fecha: 2004-07-30 Intervenciones: Drug: SOM230 s.c.
Completed	Nombre del estudio: Interdisciplinary Pituitary Disorders Centre of Excellence: Assessment of Patient Education Tools Condición: Pituitary Neoplasms Prolactinoma ACT Fecha: 2013-01-22 Intervenciones: Other: Educational Intervention A brochure and access to a website including videos that contain detaile
Completed	Nombre del estudio: Effects of Hormone Stimulation on Brain Scans for Cushing s Disease Condición: Pituitary Neoplasm Fecha: 2011-10-21 Intervenciones: Drug: Acthrel Ovine Corticorelin
Active, not recruiting	Nombre del estudio: Rhinological Outcomes in Endonasal Pituitary Surgery Condición: Pituitary Neoplasm Pituitary Adenoma Prolactinoma Fecha: 2012-01-03
Completed	Nombre del estudio: Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in a Novartis-sponsored Study. Condición: Cushing's Disease Acromegaly Fecha: 2013-02-15 Intervenciones: Drug: Pasireotide Pasireotide subcutaneous or Long Acting Release
Completed	Nombre del estudio: Pasireotide LAR Therapy of Silent Corticotroph Pituitary Tumors Condición: Pituitary Tumor ACTH-producing Pituitary Tumour Fecha: 2016-04-20 Intervenciones: Drug: Pasireotide LAR Pasireotide LAR (SIGNIFOR® LAR)